Boston Scientific
Boston Scientific
5 Projects, page 1 of 1
assignment_turned_in Project2020 - 2025Partners:Terumo Vascutek, Massachusetts Institute of Technology, SIEMENS PLC, MIT, Polytechnic University of Milan +33 partnersTerumo Vascutek,Massachusetts Institute of Technology,SIEMENS PLC,MIT,Polytechnic University of Milan,Kirkstall Ltd,University of Glasgow,Massachusetts Institute of Technology,NHS Research Scotland,NHS GREATER GLASGOW AND CLYDE,Scottish Health Innovations Ltd,InSilicoTrials Technologies,GSK,BTL,GlaxoSmithKline PLC,Siemens plc (UK),Boston Scientific,Humanitas University,Kirkstall Ltd,3DS,NHS Research Scotland,University of Glasgow,Dassault Systèmes (United Kingdom),InnoScot Health,Vascular Flow Technologies,Biomer Technology Ltd,BSC,Translumina GmbH,NHS Greater Glasgow and Clyde,GlaxoSmithKline (Harlow),Vascular Flow Technologies,Humanitas University,NHS Greater Glasgow and Clyde,Terumo Vascutek,Translumina GmbH,3DS,InSilicoTrials Technologies,Dassault Systemes UK LtdFunder: UK Research and Innovation Project Code: EP/S030875/1Funder Contribution: 1,599,530 GBPSoft tissue related diseases (heart, cancer, eyes) are among the leading causes of death worldwide. Despite extensive biomedical research, a major challenge is a lack of mathematical models that predict soft tissue mechanics across subcellular to whole organ scales during disease progression. Given the tremendous scope, the unmet clinical needs, our limited manpower, and the existence of complementary expertise, we seek to forge NEW collaborations with two world-leading research centres: MIT and POLIMI, to embark on two challenging themes that will significantly stretch the initial SofTMech remit: A) Test-based microscale modelling and upscaling, and B) Beyond static hyperelastic material to include viscoelasticity, nonlinear poroelasticity, tissue damage and healing. Our research will lead to a better understanding of how our bodies work, and this knowledge will be applied to help medical researchers and clinicians in developing new therapies to minimise the damage caused by disease progression and implants, and to develop more effective treatments. The added value will be a major leap forward in the UK research. It will enable us to model soft tissue damage and healing in many clinical applications, to study the interaction between tissue and implants, and to ensure model reproducibility through in vitro validations. The two underlying themes will provide the key feedback between tissue and cells and the response of cells to dynamic local environments. For example, advanced continuum mechanics approaches will shed new light on the influence of cell adhesion, angiogenesis and stromal cell-tumour interactions in cancer growth and spread, and on wound healing implant insertion that can be tested with in vitro and in vivo systems. Our theoretical framework will provide insight for the design of new experiments. Our proposal is unique, timely and cost-effectively because advances in micro- and nanotechnology from MIT and POLIMI now enable measurements of sub-cellular, single cell, and cell-ECM dynamics, so that new theories of soft tissue mechanics at the nano- and micro-scales can be tested using in vitro prototypes purposely built for SofTMech. Bridging the gaps between models at different scales is beyond the ability of any single centre. SofTMech-MP will cluster the critical mass to develop novel multiscale models that can be experimentally tested by biological experts within the three world-leading Centres. SofTMech-MP will endeavour to unlock the chain of events leading from mechanical factors at subcellular nanoscales to cell and tissue level biological responses in healthy and pathological states by building a new mathematics capacity. Our novel multiscale modelling will lead to new mathematics including new numerical methods, that will be informed and validated by the design and implementation of experiments at the MIT and POLIMI centres. This will be of enormous benefit in attacking problems involving large deformation poroelasticity, nonlinear viscoelasticity, tissue dissection, stent-related tissue damage, and wound healing development. We will construct and analyse data-based models of cellular and sub-cellular mechanics and other responses to dynamic local anisotropic environments, test hypotheses in mechanistic models, and scale these up to tissue-level models (evolutionary equations) for growth and remodelling that will take into account the dynamic, inhomogeneous, and anisotropic movement of the tissue. Our models will be simulated in the various projects by making use of the scientific computing methodologies, including the new computer-intensive methods for learning the parameters of the differential equations directly from noisy measurements of the system, and new methods for assessing alternative structures of the differential equations, corresponding to alternative hypotheses about the underlying biological mechanisms.
more_vert assignment_turned_in Project2008 - 2013Partners:Luxfer Gas Cylinders Ltd, Bayer plc, 3dMD Ltd, NHS Purchasing and Supply Agency, 3M Health Care Ltd +75 partnersLuxfer Gas Cylinders Ltd,Bayer plc,3dMD Ltd,NHS Purchasing and Supply Agency,3M Health Care Ltd,Sensor Technology & Devices Ltd,Zimmer GmbH,Baxter (United States),Molnlycke Healthcare Ltd,Olympus Optical Co (UK),BFC,ABA Adams Business Associates,Smith and Nephew Healthcare Ltd,NHS Purchasing and Supply Agency,OBS Medical (United Kingdom),Bayer AG,Molnlycke Healthcare Ltd,NHS Institute for Innovation and Improve,Plus Orthopedics UK Ltd,Plus Orthopedics UK Ltd,Translucency Ltd,Partnerships for Health,Active4Life Healthcare Technologies Ltd,Smiths Group plc,Partnerships for Health,Corin Group PLC,National Patient Safety Agency,HeartSine Technologies Ltd,Anson Medical Ltd,Smith and Nephew Healthcare Ltd,3M United Kingdom Plc,Brunel University,Triteq Ltd,Corin Group PLC,Boston Scientific,Finsbury Orthopaedics Ltd,Invest Northern Ireland,Brunel University London,NPSA,Translucency Ltd,DePuy Synthes (International),ABA Adams Business Associates,DePuy Orthopaedics Inc,Astron Clinica,Olympus Optical Co (UK),Cinimod IP Ltd,Sensor Technology & Devices Ltd,Invest Northern Ireland,Moor Instruments (United Kingdom),British Council,Cinimod IP Ltd,Smith and Nephew UK Limited,Anson Medical Ltd,3M Health Care Ltd,Investment Belfast,3dMD Ltd,HeartSine Technologies Ltd,MSI Consultancy Ltd,Oxford BioSignals Ltd,Finsbury Orthopaedics Ltd,Apatech Ltd,Datalink Electronics,Moor Instruments Ltd,BSC,Luxfer Gas Cylinders Ltd,Active4Life Healthcare Technologies Ltd,Orthodocs Ltd,Astron Clinica,Triteq Ltd,Pearson Matthews Design Partnership,Datalink Electronics,NHS Institute for Innovation and Improve,Zimmer GmbH,Pearson Matthews Design Partnership,Baxter International Inc,Smiths Group plc,Apatech Ltd,Investment Belfast,Bayer CropScience UK,MSI Consultancy LtdFunder: UK Research and Innovation Project Code: EP/F063822/1Funder Contribution: 6,760,670 GBPTo maintain continuity with MATCH Phase 1, it has been requested that MATCH Phase 2 follows the current programme breakdown in terms of Projects A-F from 2008-2013 / a vision that is described below. We note that MATCH changed dramatically in creating the projects A-F and that further changes in the themes are inevitable. An overview of these themes is given below.Projects A, B and C address economic evaluation and its impact in decision-making by companies, governments and procurement agencies. We have identified a major demand for such research, but note that there is some convergence between these themes (for instance, A and C may well coalesce under the Bayesian banner). In particular, a 'methodologies' theme is likely to emerge in this. Under the former theme, a truly integrated Bayesian framework for medical devices would represent a strategically important achievement.On the other hand, the business of delivering these developments to industry, and the organisations or franchises that might ultimately provide the best vehicle for doing so, still requires further exploration and negotiation, and at this point there is considerable uncertainty about how this will best be done. However the critical element has been established, namely that MATCH can provide useful tools for, and attract significant levels of funding from industry. To this extent, the applied side of Project A-F and Project 5 might well evolve into a series of programmes designed to spin out tools, training and best practice into industry. Project 5 remains for the present because we have set it up with a framework within which company IP can be protected, and within which we can expedite projects to company goals and time scales.A similar pattern is likely to emerge from the single User project (D), where there is considerable scope for capability, and methodological development / and the size of this team needs to increase. The aim is to develop a suite of methods, guidelines and examples, describing when a given method is useful and when user needs assessment must be cost-effective. We will gain and share experience on what approach works best where. Our taxonomy will recognise circumstances where the novelty of a proposed device may undermine the validity of user needs assessment conducted before the 'technological push' has had a fair opportunity to impact on the human imagination.Moreover, new research is needed to 'glue' some of these themes together. Some of this is already included (for instance, in Projects C and D below) to link the user-facing social science with the economics, or the pathway-changing experiences (F) with formal economic evaluation, will require new, cross-disciplinary research. This type of research is essential to developing the shared view of value, which MATCH is pursuing. Similarly, integrating supply-chain decision-making and procurement elements of theme (E) with economic evaluation would represent an important element of unification.To achieve this, we will need to bring in some news skills. For instance, we are already freeing up some funding to bring in an economics researcher at Ulster; more statistical mathematical support may be needed to further develop the Bayesian theme; and we need to bolster the sociological element within the team.Finally, this vision cannot be funded entirely within a research framework, and we expect critical elements to be achieved under other funding (for instance, Theme E by the NHS, in due course).
more_vert assignment_turned_in Project2021 - 2026Partners:Golden Jubilee National Hospital, XJTLU, NHS Research Scotland, University of Glasgow, North Carolina State University +30 partnersGolden Jubilee National Hospital,XJTLU,NHS Research Scotland,University of Glasgow,North Carolina State University,3DS,NHS Golden Jubilee,GlaxoSmithKline PLC,NHS Greater Glasgow and Clyde,Royal Papworth Hospital NHS Fdn Trust,University of Glasgow,Xi'an Jiaotong University,InfraredX,BSC,South Warwickshire Hospitals NHS Trust,Dassault Systèmes (United Kingdom),Xi'an Jiatong University,NHS Research Scotland,Boston Scientific,GlaxoSmithKline (Harlow),NCSU,Royal Papworth Hospital NHS Fdn Trust,3DS,NHS Greater Glasgow and Clyde,GSK,Insigneo Institute,Translumina GmbH,InnoScot Health,Scottish Health Innovations Ltd,NHS GREATER GLASGOW AND CLYDE,South Warwickshire Hospitals NHS Trust,Insigneo Institute,Dassault Systemes UK Ltd,Translumina GmbH,InfraredXFunder: UK Research and Innovation Project Code: EP/T017899/1Funder Contribution: 1,225,130 GBPThere have recently been impressive developments in the mathematical modelling of physiological processes. As part of a previously EPSRC-funded research centre (SofTMech), we have developed mathematical models for the mechanical and electrophysiological processes of the heart, and the flow in the blood vessel network. This allows us to gain deeper insight into the state of a variety of serious cardiovascular diseases, like hypoxia (a condition in which a region of the body is deprived of adequate oxygen supply), angina (reduced blood flow to the heart), pulmonary hypertension (high blood pressure in the lungs) and myocardial infarction (heart attack). A more recent extension of this work to modelling blood flow in the eye also provides novel indicators to assess the degree of traumatic brain injury. What all these models have in common is a complex mathematical description of the physiological processes in terms of differential equations that depend on various material parameters, related e.g. to the stiffness of the blood vessels or the contractility of the muscle fibres. While knowledge of these parameters would be of substantial benefit to the clinical practitioner to help them improve their diagnosis of the disease status, most of the parameters cannot be measured in vivo, i.e. in a living patient. For instance, the determination of the stiffness and contractility of the cardiac tissue would require the extraction of the heart from a patient and its inspection in a laboratory, which can only be done in a post mortem autopsy. It is here that our mathematical models reveal their diagnostic potential. Our equations of the mechanical processes in the heart predict the movement of the heart muscle and how its deformations change in time. These movements can also be observed with magnetic resonance image (MRI) scans, and they depend on the physiological parameters. We can thus compare the predictions from our model with the patterns found in the MRI scans, and search for the parameters that provide the best agreement. In a previous proof-of-concept study we have demonstrated that the physiological parameters identified in this way lead to an improved understanding of the cardiac disease status, which is important for deciding on appropriate treatment options. Unfortunately, the calibration procedure described above faces enormous computational costs. We typically have a large number of physiological parameters, and an exhaustive search in a high-dimensional parameter space is a challenging problem. In addition, every time we change the parameters, our mathematical equations need to be solved again. This requires the application of complex numerical procedures, which take several minutes to converge. The consequence is that even with a high-performance computer, it takes several weeks to determine the physiological parameters in the way described above. It therefore appears that despite their enormous potential, state of the art mathematical modelling techniques can never be practically applied in the clinical practice, where diagnosis and decisions on alternative treatment option have to be made in real time. Addressing this difficulty is the objective of our proposed research. The idea is to approximate the computationally expensive mathematical model by a computationally cheap surrogate model called an emulator. To create this emulator, we cover the parameter space with an appropriate design, solve the mathematical equations in parallel numerically for the chosen parameters, and then fit a non-linear statistical regression model to this training set. After this initial computational investment, the emulator thus created gives predictions for new parameter values practically instantaneously, allowing us to carry out the calibration procedure described above in real time. This will open the doors to harnessing the diagnostic potential of state-of-the art mathematical models for improved decision support in the clinic.
more_vert assignment_turned_in Project2014 - 2018Partners:Cybula Ltd, BSC, Roke Manor Research Ltd, Cybula Ltd, Cybula Limited +6 partnersCybula Ltd,BSC,Roke Manor Research Ltd,Cybula Ltd,Cybula Limited,Boston Scientific,Intel (United States),Imperial College London,RMRL,Covidien,Intel CorporationFunder: UK Research and Innovation Project Code: EP/L014149/1Funder Contribution: 3,027,640 GBPRecent advances in surgery have made a significant impact on the management of major acute diseases, prolonging life and continuously pushing the boundaries of survival. Despite increasing sophistication of surgical intervention, complications remain common and poorly understood, contributing significantly to mortality and morbidity. Surgical site infections, catheter related sepsis, wound dehiscence and gastrointestinal anastomotic leakage are recognised complications following surgical interventions or invasive monitoring of critically ill surgical patients. Current methods for detecting these complications rely on episodic clinical examination with 'snap shot' laboratory testing. There is therefore a pressing need to develop new sensing technologies that can be seamlessly integrated with existing surgical appliances to provide continuous sensing and early detection of these adverse events, thus minimising post-operative infection, complication, and readmission. All these will also have a direct impact on healthcare economics, and more importantly the prognosis and quality-of-life of patients after surgery. The proposed project is organised into three research themes: 1) Multimodal Sensing and Miniaturised Embodiment; 2) Active Sensing with Low Power Microelectronics; and 3) Data Inferencing and Stratified Patient Management. These research themes address key technical issues related to sensor design, miniaturisation, and self-calibration, as well as low-power on-node processing, inferencing, and clinical decision support. These research themes are connected by three clinical exemplars in surgical sensing with increasing levels of technical complexity. The vision is to develop smart sensors integrated with surgical appliances and to be inserted in close proximity to the surgical site, encased within surgical drains/catheters, or placed in locations to more seamlessly monitor the systemic inflammatory response. The devices will be implanted during elective surgery or at biopsy, interrogated wirelessly, and eliminated by natural processes, or routine removal of 'hosts' such as the drains or catheters. The research programme is underpinned by extensive experience of the team in body sensor networks and bio-photonics in healthcare. Through an integrated programme of engineering research and development of a novel real-time active sensing paradigm, the project aims to transform the care pathways for surgery with greater consideration on personalised treatment, system level impact, real-time response to complications, patient concordance and quality of life. We expect that the outcome of the research will help improve surgical workflows, support safe discharge and home/community-based recovery, reduce unplanned readmissions, and influence the future of healthcare policy.
more_vert assignment_turned_in Project2024 - 2028Partners:University of Glasgow, Medis Medical Imaging System, Columbia University, Aarhus University Hospital, Golden Jubilee National Hospital +8 partnersUniversity of Glasgow,Medis Medical Imaging System,Columbia University,Aarhus University Hospital,Golden Jubilee National Hospital,POLITO,Boston Scientific,Pie Medical Imaging,MedAlliance Ltd,Abbott Vascular,Translumina GmbH,CARDIOVASCULAR RESEARCH CENTER AALST VZW,Biosensors Europe SAFunder: UK Research and Innovation Project Code: EP/Z531182/1Funder Contribution: 1,275,540 GBPPercutaneous Coronary Intervention (PCI) is a common clinical procedure used to treat obstructive coronary artery disease, one of the leading causes of death. The overwhelming majority of patients will receive drug-eluting stent devices that act as a supporting scaffold and deliver drugs to counteract renarrowing. While this technology has been truly revolutionary, hundreds of thousands of patients worldwide annually still require an invasive repeat procedure, representing a huge economic burden on society and increasing pressure on health care resources. The key issue is that it is currently not feasible to quantitatively predict the immediate effect of a specific intervention and if/when a patient will suffer from renarrowing in the longer-term. Tools that enable optimisation of the procedure on a patient-specific basis are therefore urgently needed to improve patient outcomes and alleviate the resource burden on healthcare providers. Critical to optimising the procedure is assessment of the individual patient's level of disease. Advances in medical imaging technology now make it possible to visualise the degree of obstruction and, crucially, the composition of the underlying plaque, potentially providing clinicians with a wealth of information to inform and plan PCI. However, decisions are presently left to operator experience and there are no definitive guidelines for how to optimise PCI for a given patient, particularly in complex cases. In recent years, we have seen significant developments in computational models of PCI, that have the potential to inform PCI strategy in the future. However, they suffer from limitations and significant methodological advances are required before they can be routinely integrated within the clinic. These primarily relate to increasing the realism and accuracy of the models, improving their robustness, predictive power and speed of computation. This last point is critical, with the exorbitant run times of current computational models significantly hampering timely decision support and genuine impact in the clinic. The EPSRC Centre for Future PCI Planning will address these challenges by developing a computational decision support tool to assist clinicians with PCI planning. Advances in mathematical modelling of fluid-structure interaction, lesion preparation, drug delivery and growth & remodelling, allied to statistical inference, emulation, uncertainty quantification and optimisation will enable us to create computational tools able to answer key clinical questions like: 1) What will a given patient's artery look like immediately after device deployment? 2) How should the plaque be modified prior to stent deployment, and what specialist tools should be used to do this? 3) What length and diameter of stent should be used, and what should be the balloon deployment inflation pressure? 4) What is the optimal placement of the stent? 5) In the case of complex bifurcation lesions, where potentially multiple stents and balloons are deployed, what is the optimal technique? 6) To what extent is the artery likely to renarrow, over what time course, and how can the PCI strategy be optimised to avoid this? 7) Can we effectively plan PCI solely on pre-procedural imaging such as Computed Tomography? Working together with world-leading International Centres, and a range of leading imaging and medical device companies, the EPSRC Centre for Future PCI Planning will develop novel and robust mathematical and statistical methodologies, supported by large clinical data sets, to create the novel, fast and accurate tools that will help realise our vision of integrating computational tools for PCI planning within the clinic.
more_vert
